Pituitary abnormalities in Prader-Willi syndrome and early onset morbid obesity

被引:55
作者
Miller, Jennifer L. [1 ]
Goldstone, Anthony P. [2 ]
Couch, Jessica A. [3 ]
Shuster, Jonathan [4 ]
He, Guojun [3 ]
Driscoll, Daniel J. [1 ,5 ]
Liu, Yijun [3 ]
Schmalfuss, Ilona M. [6 ]
机构
[1] Univ Florida, Dept Pediat, Coll Med, Div Pediat Endocrinol,JHMHC, Gainesville, FL 32610 USA
[2] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, MRC, Ctr Clin Sci,Imaging Sci Dept, London, England
[3] Univ Florida, Dept Psychiat, Coll Med, Gainesville, FL 32611 USA
[4] Univ Florida, Dept Epidemiol & Hlth Policy Res, Gainesville, FL USA
[5] Univ Florida, Coll Med, Ctr Mammalian Genet, Gainesville, FL USA
[6] Univ Florida, Dept Radiol, VAMC, Gainesville, FL 32610 USA
基金
英国医学研究理事会;
关键词
early onset obesity; Prader-Willi syndrome; pituitary gland;
D O I
10.1002/ajmg.a.31677
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Prader-Willi syndrome (PWS) is a well-defined syndrome of childhood-obesity which can serve as a model for investigating early onset childhood obesity. Many 4 the clinical features of PWS (e.g., hyperphagia, hypogonadotropic hypogonadism, growth hormone deficiency) are hypothesized to be due to abnormalities of the hypothalamus and/or pituitary gland. Children who become severely obese very early in life (i.e., before age 4 years) may also have a genetic etiology of their obesity, perhaps with associated neuroendocrine and hypothalamo-pituitary defects, as infants and very young children have limited access to environmental factors that contribute to obesity. We hypothesized that morphologic abnormalities of the pituitary gland would be seen in both individuals with PWS and other Subjects with early onset morbid obesity (EMO). This case-control study included individuals with PWS (n = 27, age 3 months to 39 years), patients with EMO of unknown etiology (n = 16, age 4-22 years; defined as body mass index greater than the 97th centile for age before age 4 years), and normal weight siblings (n = 25, age 7 months to 43 years) from both groups. Participants had 3-dimensional magnetic resonance imaging to evaluate the pituitary gland, a complete history and physical examination, and measurement of basal pituitary hormones. Subjects with PWS and EMO had a higher prevalence of pituitary morphological abnormalities than did control subjects (74% PWS: 69% EMO, 8% controls; P < 0.001). Anterior pituitary hormone deficiencies were universal in individuals with PWS (low IGF-1 in 100%, P < 0.001 PWS vs. controls; central hypothyroidism in 19%, P = 0.052, and hypoplastic genitalia or hypogonadotropic hypogonadism in 100%, P < 0.001), and was often seen in individuals with EMO (6%, P = 0.89 vs. control, 31%, P = 0.002, and 25%, P = 0.018, respectively). The presence of a hypoplastic pituitary gland appeared to correlate with the presence of anterior pituitary hormone deficiencies in individuals with EMO, but no correlation was apparent in individuals with PWS. In conclusion, the high frequency of both morphological and hormonal abnormalities of the pituitary gland in both individuals with PWS and EMO suggests that abnormalities in the hypothalamo-pituitary axis are features not only of PWS, but also frequently of EMO of unknown etiology. (C) 2007 Wiley-Liss, Inc.
引用
收藏
页码:570 / 577
页数:8
相关论文
共 50 条
  • [21] Prader-Willi syndrome
    Kundert, Deborah King
    SCHOOL PSYCHOLOGY QUARTERLY, 2008, 23 (02) : 246 - 257
  • [22] Successful rapid weight reduction and the use of liraglutide for morbid obesity in adolescent Prader-Willi syndrome
    Kim, Yoo-Mi
    Lee, Yeoun Joo
    Kim, Soo Yeon
    Cheon, Chong Kun
    Lim, Han Hyuk
    ANNALS OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2020, 25 (01) : 52 - 56
  • [23] Surgical treatment of morbid obesity associated to Prader-Willi syndrome.: Report of one case
    Braghetto, I
    Rodríguez, A
    Debandi, A
    Brunet, L
    Papapietro, K
    Pineda, P
    Pacheco, MI
    REVISTA MEDICA DE CHILE, 2003, 131 (04) : 427 - 431
  • [24] BioEnterics Intragastric Balloon for Treatment of Morbid Obesity in Prader-Willi Syndrome: Specific Risks and Benefits
    De Peppo, F.
    Di Giorgio, G.
    Germani, M.
    Ceriati, E.
    Marchetti, P.
    Galli, C.
    Ubertini, M. G.
    Spera, S.
    Ferrante, G.
    Cuttini, M.
    Cappa, M.
    Gattinara, G. Castelli
    Rivosecchi, M.
    Crino, A.
    OBESITY SURGERY, 2008, 18 (11) : 1443 - 1449
  • [25] Prader-Willi syndrome
    Cassidy, Suzanne B.
    Schwartz, Stuart
    Miller, Jennifer L.
    Driscoll, Daniel J.
    GENETICS IN MEDICINE, 2012, 14 (01) : 10 - 26
  • [26] Prader-Willi syndrome
    Cassidy, SB
    JOURNAL OF MEDICAL GENETICS, 1997, 34 (11) : 917 - 923
  • [27] Prader-Willi Syndrome: Obesity due to Genomic Imprinting
    Butler, Merlin G.
    CURRENT GENOMICS, 2011, 12 (03) : 204 - 215
  • [28] Intensive management of obesity in people with Prader-Willi syndrome
    Nolan, Brendan J.
    Proietto, Joseph
    Sumithran, Priya
    ENDOCRINE, 2022, 77 (01) : 57 - 62
  • [29] Prader-Willi syndrome: an update on obesity and endocrine problems
    Kim, Su Jin
    Cho, Sung Yoon
    Jin, Dong-Kyu
    ANNALS OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2021, 26 (04) : 227 - 236
  • [30] Is ghrelin a biomarker of early-onset scoliosis in children with Prader-Willi syndrome?
    Alfaro, Dibia Liz Pacoricona
    Diene, Gwenaelle
    Pinto, Graziella
    Salles, Jean-Pierre
    Gennero, Isabelle
    Faye, Sandy
    Molinas, Catherine
    Valette, Marion
    Arnaud, Catherine
    Tauber, Maithe
    ORPHANET JOURNAL OF RARE DISEASES, 2021, 16 (01)